RAMIFENTANYL
Solid Organ Cancer
Peking University First HospitalSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Solid Organ Cancer cohort.
View all 9 →
Same molecule, other indications
RAMIFENTANYL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →